Compare
Indivior Pharmaceuticals, Inc. vs Prestige Consumer Healthcare Inc. vs Alkermes plc. vs ANI Pharmaceuticals Inc
| Latest fiscal year | Indivior Pharmaceuticals, Inc. INDV | Prestige Consumer Healthcare Inc. PBH | Alkermes plc. ALKS | ANI Pharmaceuticals Inc ANIP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.24B | $1.09B | $1.48B | $883.37M |
| Revenue growth (YoY) | +4.3% | -4.3% | -5.2% | +43.8% |
| Gross margin | 80.2% | 54.7% | 86.7% (computed) | n/a |
| Operating margin | 21.1% | 28.4% | 17.2% | 12.6% |
| Net margin | 16.9% | 17.5% | 16.4% | 8.9% |
| Net income | $210.00M | $190.30M | $241.66M | $78.34M |
| EPS (Diluted) | $1.64 | $3.91 | $1.43 | $3.32 |
| Operating cash flow | -$27.00M | $257.63M | $520.75M | $185.22M |
| Free cash flow | -$93.00M | $246.45M | $480.33M | $171.39M |
| Cash & equivalents | $195.00M | $63.87M | $388.57M | $285.58M |
| Total assets | $1.20B | $3.49B | $2.49B | $1.44B |
| Total liabilities | $1.30B | $1.61B | $667.70M | $899.65M |
| Shareholders' equity | -$98.00M | $1.89B | $1.82B | $540.72M |
| Return on year-end equity | n/a | 10.1% | 13.3% | 14.5% |
| Shares outstanding | n/a | n/a | 165.61M | 22.49M |
Revenue, most recent five fiscal years
| Fiscal year | Indivior Pharmaceuticals, Inc. | Prestige Consumer Healthcare Inc. | Alkermes plc. | ANI Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $1.24B Ended 2025-12-31 | $1.09B Ended 2026-03-31 | $1.48B Ended 2025-12-31 | $883.37M Ended 2025-12-31 |
| 1 year earlier | $1.19B Ended 2024-12-31 | $1.14B Ended 2025-03-31 | $1.56B Ended 2024-12-31 | $614.38M Ended 2024-12-31 |
| 2 years earlier | $1.09B Ended 2023-12-31 | $1.13B Ended 2024-03-31 | $1.66B Ended 2023-12-31 | $486.82M Ended 2023-12-31 |
| 3 years earlier | $901.00M Ended 2022-12-31 | $1.13B Ended 2023-03-31 | $1.11B Ended 2022-12-31 | $316.38M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.09B Ended 2022-03-31 | $1.17B Ended 2021-12-31 | $216.14M Ended 2021-12-31 |